In vivo visualization of gene expression using magnetic resonance imaging

Division of Biology Beckman Institute, California Institute of Technology, Pasadena, CA 91125, USA.
Nature Biotechnology (Impact Factor: 39.08). 04/2000; 18(3):321-5. DOI: 10.1038/73780
Source: PubMed

ABSTRACT High-resolution in vivo imaging of gene expression is not possible in opaque animals by existing techniques. Here we present a new approach for obtaining such images by magnetic resonance imaging (MRI) using an MRI contrast agent that can indicate reporter gene expression in living animals. We have prepared MRI contrast agents in which the access of water to the first coordination sphere of a chelated paramagnetic ion is blocked with a substrate that can be removed by enzymatic cleavage. Following cleavage, the paramagnetic ion can interact directly with water protons to increase the MR signal. Here, we report an agent where galactopyranose is the blocking group. This group renders the MRI contrast agent sensitive to expression of the commonly used marker gene, beta-galactosidase. To cellular resolution, regions of higher intensity in the MR image correlate with regions expressing marker enzyme. These results offer the promise of in vivo mapping of gene expression in transgenic animals and validate a general approach for constructing a family of MRI contrast agents that respond to biological activity.

Download full-text


Available from: Rex A Moats, Jun 20, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Two major initiatives to accelerate research in the brain sciences have focused attention on developing a new generation of scientific instruments for neuroscience. These instruments will be used to record static (structural) and dynamic (behavioral) information at unprecedented spatial and temporal resolution and report out that information in a form suitable for computational analysis. We distinguish between recording - taking measurements of individual cells and the extracellular matrix - and reporting - transcoding, packaging and transmitting the resulting information for subsequent analysis - as these represent very different challenges as we scale the relevant technologies to support simultaneously tracking the many neurons that comprise neural circuits of interest. We investigate a diverse set of technologies with the purpose of anticipating their development over the span of the next 10 years and categorizing their impact in terms of short-term [1-2 years], medium-term [2-5 years] and longer-term [5-10 years] deliverables.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The unambiguous detection of specific neuronal subtypes is up to now only possible with invasive techniques or optical imaging after genetic modification. High field magnetic resonance imaging (MRI) has the ability to visualize the brain structure and anatomy noninvasively, with high resolution--but missing the cell specific and functional information. Here we present a new tool for neuroimaging with MRI, enabling the selective detection of GABAergic neurons under in vivo conditions. The specific imaging contrast is achieved by a novel paramagnetic contrast agent, which responds to the activity of the enzyme glutamic acid decarboxylase--expressed solely by inhibitory neurons. The relaxivity of the complex is increased upon decarboxylation of two glutamic acid moieties, thus allowing increased water access to the inner and outer coordination spheres of the paramagnetic ion. The mechanism and specificity of activation were proven with tissue lysates and further applied to a differentiation protocol for murine embryonic stem cells. The relaxation enhancement was studied quantitatively and revealed decreased longitudinal relaxation times in the inhibitory neuron samples compared to the naïve stem cells in vitro and in vivo. Furthermore, this approach offers not only the discrimination of inhibitory, GABAergic neurons in the brain but also may expand the usefulness of MRI for functional imaging on a cellular level.
    NeuroImage 05/2012; 62(3):1685-93. DOI:10.1016/j.neuroimage.2012.05.029 · 6.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MnO nanoparticles have been tested to engineer a delayed increase in MRI T(1) relaxivity caused by cellular uptake via endocytosis into acidic compartments. Various coatings on core-shell structured MnO nanoparticles were tested for those that had the lowest T(1) relaxivity at pH 7.4, a pH where MnO does not dissolve into Mn(2+) ions. The rate of dissolution and release of Mn(2+) of the different coated MnO particles as well as changes in T(1) relaxivity were measured at pH 5, a pH routinely obtained in the endosomal-lysosomal pathway. Of a number of coatings, silica coated MnO (MnO@SiO(2)) had the lowest relaxivity at pH 7.4 (0.29 mm(-1) sec(-1)). About one third of the MnO dissolved within 20 min and the T(1) relaxivity increased to that of free Mn(2+) (6.10 mm(-1) sec(-1)) after three days at pH 5. MRI of MnO@SiO(2) particles injected into the rat brain showed time-dependent signal changes consistent with the in vitro rates. Thalamocortical tract-tracing could be observed due to the released Mn(2+). Intravenous infusion of MnO@SiO(2) particles showed little enhancement in any tissue except gallbladder. The gallbladder enhancement was interpreted to be due to endocytosis by liver cells and excretion of Mn(2+) ions into the gallbladder. The MnO@SiO(2) core-shell nanoparticles show the best potential for delaying the release of MRI contrast until endocytosis into low pH compartments activate MRI contrast. The delayed enhancement may have benefits for targeting MRI contrast to specific cells and surface receptors that are known to be recycled by endocytosis.
    Biomaterials 05/2012; 33(13):3560-7. DOI:10.1016/j.biomaterials.2012.01.062 · 8.31 Impact Factor